Charles River Laboratories Intl. Inc vs Payoneer Global Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.95 (market cap $14.23B), while Payoneer Global Inc trades at $7.15 (market cap $2.43B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 5.9× Payoneer Global Inc's market cap, and Payoneer Global Inc is more actively traded (1,342,701 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Payoneer Global Inc for 61 Days on average.
| CRL | PAYO | |
|---|---|---|
Market Cap | $14.23B | $2.43B |
Volume | 1,176,885 | 1,342,701 |
Sector | Health | Technology |
52-Week High | $310.77 | $7.18 |
52-Week Low | $149.93 | $4.27 |
Typical Hold Time | 33 Days | 61 Days |
Enterprise Value | $17.06B | $2.17B |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Payoneer Global (PAYO) trades at $7.15, down slightly by 0.14% with a bullish technical signal from moving averages. The company reported Q2 2026 earnings of $0.02 per share, missing estimates, but revenue grew 10% excluding interest. Recent news highlights Payoneer's renewed partnership with Etsy through 2029 and the company's agreement to be acquired by Nuvei announced in June 2026. Analyst sentiment remains positive with 60% buy ratings despite recent earnings volatility.
The acquisition by Nuvei creates near-term upside potential, but execution risks and margin compression pose challenges. Revenue growth remains solid at 15% volume growth year-over-year, though net income margin has declined from 16.8% in 2024 to 5.8% projected for 2026. The stock's valuation at 51x P/E appears stretched relative to earnings growth, suggesting cautious optimism is warranted.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →